Baird lowered the firm’s price target on Certara (CERT) to $13 from $18 and keeps a Neutral rating on the shares. The firm views recent CRO reports noting downward adjustments in pharma spending toward the end of 3Q24 as increasing risks that Certara sees more muted 4Q24 seasonality and FY25 improvement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERT:
- Certara price target lowered to $14 from $16 at Barclays
- Wynn Resorts upgraded, HP Inc. downgraded: Wall Street’s top analyst calls
- Certara upgraded to Buy from Neutral at UBS
- Certara, ICI shares results from its collaboration on ISB 2001
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
